Почетна › Hronična mijelomonocitna leukemija › Kalifornija
Kliničke studije za Hronična mijelomonocitna leukemija u državi Kalifornija
12 studija za Hronična mijelomonocitna leukemija traži učesnike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Zvanični tekst studije (na engleskom)
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06543381Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- Orso Health, La Jolla
- Kaiser Permanente San Diego, San Diego
- Allergy & Asthma Clinical Research of the Bay Area, Walnut Creek
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT07143669A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT04996875TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
Тражи се учесникФаза 1
Узраст од 18 до 80 · Оба пола · Ажурирано 17. 8. 2026. · NCT07302776Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 29. 6. 2026. · NCT06815003A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- City of Hope, Duarte
- Stanford Medical Center, Palo Alto
Тражи се учесникФаза 1
Узраст 12 и старији · Оба пола · Ажурирано 16. 3. 2026. · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Stanford University, Stanford
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT06950034Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- University of California Davis Health (UC Davis Health), Sacramento
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 1. 2026. · NCT05184842Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- University of California Irvine, Irvine
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2025. · NCT03850574Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 4. 2025. · NCT06462365Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.